Trinity Biotech Appoints Aris Kekedjian as CEO

Trinity Biotech, a maker of diagnostic products for point-of-care and laboratories, has named Aris Kekedjian as its new CEO, effective today. He succeeds co-founder Ronan O’Caoimh, who will remain on the company’s board.
 
Kekedjian also assumed the role of chairman. He brings over 30 years of business leadership to the company, with a three-decade career at GE that culminated in a position as chief investment officer and global head of business development.
 
Most recently, Kekedjian was president and CEO of Icahn Enterprises, senior advisor to ECN Capital, and an independent director at Xeros, Finserv Acquisition, and XPO Logistics.
 
“I am delighted that Aris Kekedjian, the former Chief Investment Officer of GE, a company with a long history of world leading diagnostics and life sciences businesses, has agreed to lead Trinity Biotech as CEO. Throughout his career, Aris has a been the architect of numerous transformative portfolio strategies and has delivered rapid growth in regulated industries. He also has a track record of championing early moves in new industries or those undergoing fundamental change much like the changes now ongoing in the diagnostic industry,” outgoing CEO O’Caoimh told the press. “Aris is a results-oriented leader who believes that in a post-COVID-19 world with ever increasing healthcare costs, proactive decentralized testing solutions are part of mega-trends toward healthier lifestyles and digital health. I’m confident that with this latest appointment, we have a world class team with the experience and skillset to position Trinity Biotech as a high-growth diagnostic solutions innovator and industry consolidator.”
 
Kekedjian stated, “I am thrilled to be joining Trinity Biotech at such a pivotal point in the company’s history. We are at an inflection point where the future lies in a consumer-centric, proactive healthcare system. Convenient decentralized testing along with biometric technology and virtual care are key to this more cost-effective operating model. Trinity’s trusted brand, 30-year history of developing FDA and WHO approved decentralized testing solutions, world-class laboratory services and market-leading positions in the autoimmune, hemoglobin and life science categories are key attributes that attracted me to the Company. With its broad portfolio and depth of experience, Trinity Biotech is the ideal platform to build strategic ecosystem partnerships and acquire critical capabilities in a rapidly evolving industry. I look forward to working with the team, our partners, and shareholders to capitalize on this opportunity.”